Controlled Organoids transplantation as enabler for regenerative medicine transl...
Controlled Organoids transplantation as enabler for regenerative medicine translation
End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions f...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CLOC
Cultured Liver Organoids for Investigation and Treatment of...
2M€
Cerrado
RE-LIVER
Bottom up reconstitution of a biomimetic bioartificial liver
5M€
Cerrado
Liver Bioengineering
Ex vivo Re vascularization in Porcine Liver Bioengineering...
158K€
Cerrado
BIO2014-61377-EXP
BIOLIVER: LA DECONSTRUCCION APLICADA A LA HEPATOLOGIA.
85K€
Cerrado
ArtHep
Hepatocytes Like Microreactors for Liver Tissue Engineering
2M€
Cerrado
ORCHESTRATE
Building complex life through self organization from organ...
3M€
Cerrado
Información proyecto ORGANTRANS
Duración del proyecto: 43 meses
Fecha Inicio: 2019-11-24
Fecha Fin: 2023-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing.
ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.
ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the compassionate use exemption by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.